Ionis/Akcea tie $1.6B knot; CV bid with Novartis adds to better spin on Spinraza
With a pair of drugs devoted to what Ionis Pharmaceuticals Inc. CEO Stanley Crooke called "systematically knocking off the remaining lipid risk factors" for patients facing cardiovascular (CV) trouble, the company and its subsidiary, Akcea Therapeutics, closed their potential $1.6 billion deal with Novartis AG.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST